{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:50Z","timestamp":1753891910017,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Clonal hematopoiesis (CH) is characterized by the presence of hematopoietic stem cells (HSCs) with the potential of clonally expanding and giving rise to hematological malignancies. Clonal hematopoiesis of indeterminate potential (CHIP) is the outgrowth of a single HSC clone with an acquired somatic mutation in the absence of hematological abnormalities. CHIP variants occur with a variant allele frequency (VAF) of at least 2% in peripheral blood. This definition does not account for less frequent mutations that give rise to hematopoietic clones. Previous studies indicate an association between CH and secondary hematologic malignancies in cancer patients who receive chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To discover novel candidate CHIP mutations, including those with extremely low VAFs, we performed an in-depth characterization of low-frequency CHIP variants in a highly selected group of patients with high-grade serous ovarian cancer (HGSC) before and after neoadjuvant chemotherapy (NACT). We performed comprehensive ultra-high-depth whole-exome sequencing of circulating free DNA (cfDNA) and matched white blood cell (WBC) DNA from pre- (n=9) and post-NACT (n=9) samples from HGSC patients who had excellent response (ER; n=4) or poor response (PR; n=5) to NACT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Variants present in both the WBC DNA and cfDNA from a patient were considered candidate CHIP variants. We identified 93,088 candidate CHIP variants in 13,780 genes. Compared with pre-NACT samples, post-NACT samples tended to have fewer CHIP mutations with VAFs of less than 5%, which may reflect the negative selective pressure of chemotherapy on rare hematopoietic clones. Finally, we identified CHIP variants in tumor samples matched to the liquid biopsies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our innovative sequencing approach enabled the discovery of a large number of novel low-frequency candidate CHIP mutations, whose frequency and composition are affected by chemotherapy, in the cfDNA of patients with HGSC. The CHIP variants that were enriched after chemotherapy, if validated, might become essential predictive markers for therapy-related myeloid neoplasia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1538446","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:10:28Z","timestamp":1745899828000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Sara","family":"Corvigno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amma","family":"Asare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Celestino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ency A. Arboleda","family":"Goette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ridge T.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond N.","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingxiu C.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingzhi","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad M.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenna R.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1509703","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Babushok","year":"2015","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr1803641","article-title":"Tipping clonal hematopoiesis into transformation","volume":"379","author":"Karlsson","year":"2018","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171151","article-title":"Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation","volume":"215","author":"Nagase","year":"2018","journal-title":"J Exp Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0956","article-title":"Dynamics of age- versus therapy-related clonal hematopoiesis in long-term survivors of pediatric cancer","volume":"13","author":"Hagiwara","year":"2023","journal-title":"Cancer Discovery"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood.2019002220","article-title":"Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia","volume":"135","author":"Li","year":"2020","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with -ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-01-479188","article-title":"Clonal evolution in relapsed -mutated acute myeloid leukemia","volume":"122","author":"Kr\u00f6nke","year":"2013","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60361-3","article-title":"Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma","volume":"10","author":"Hirotsu","year":"2020","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.066","article-title":"Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer","volume":"31","author":"Lee","year":"2020","journal-title":"Cell Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153589","article-title":"Molecular profiles of serum-derived extracellular vesicles in high-grade serous ovarian cancer","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00046","article-title":"Clonal hematopoiesis in late-stage non-small-cell lung cancer and its impact on targeted panel next-generation sequencing","volume":"4","author":"Yaung","year":"2020","journal-title":"Jco Precis Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601894","article-title":"The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website","volume":"91","author":"Bamford","year":"2004","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1626","article-title":"cooperates with in AKXD-23 myeloid tumors via transactivation of proviral LTR","volume":"107","author":"Boyd","year":"2006","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"New Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.849376","article-title":"DNMT3A R882 mutations confer unique clinicopathologic features in MDS including a high risk of AML transformation","volume":"35","author":"Jawad","year":"2022","journal-title":"Modern Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840629","article-title":"Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens","volume":"131","author":"Severson","year":"2018","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13131","DOI":"10.1038\/s41598-023-40256-9","article-title":"Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma","volume":"13","author":"Anandakrishnan","year":"2023","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v8.16","article-title":"Ovarian cancer: Current\u00a0status and strategies for improving therapeutic outcomes","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8 tumor-infiltrating lymphocytes and a high CD8 \/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci United States America"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1538446\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:10:34Z","timestamp":1745899834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1538446\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1538446"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1538446","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"article-number":"1538446"}}